Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AM006 in levodopa-naive early Parkinson's disease
CTR20212118Phase 2Active
- Sponsor
- AffaMed Therapeutics
- Start
- Sep 2021
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of bempegaldesleukin in Parkinson's disease (PD), sponsored by AffaMed Therapeutics. Started Sep 2021; status: active.
02
Drugs
bempegaldesleukin
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on CTR20212118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212118.